Estrogen receptor and breast MR imaging features: A correlation study

Journal of Magnetic Resonance Imaging

Volumn 27, Issue 4, 2008, Pages 825-833

  Chen, Jeon Hor ^a,b   Baek, Hyeon Man ^a   Nalcioglu, Orhan ^a   Su, Min Ying ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Breast cancer; Estrogen receptor; Invasive ductal carcinoma; MR imaging; MR spectroscopy; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER PATIENT; CELL DIFFERENTIATION; HUMAN; KINETICS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHOLINE; FEMALE; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 41949111860     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21330     Document Type: Article

References (42)

1. Yasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 1999;10:431-437.
2. Bernoux A, de Cremoux P, Lainé-Bidron C, Martin EC, Asselain B, Magdelénat H. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat 1998;49:219-225.
3. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35.
4. Maki DD, Grossman RI. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol 2000;21:1064-1066.
5. Sanna G, Franceschelli L, Rotmensz N, et al. Brain metastases in patients with advanced breast cancer. Anticancer Res 2007;27:2865-2869.
6. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107:696-704.
7. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006;15:219-225.
8. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003;97:545-553.
9. Wronski M, Arbit E, McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer 1997;80:1746-1754.
10. Montemurro F, Martincich L, Sarotto I, et al. Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. Eur Radiol 2007;17:1490-1497.
11. Mussurakis S, Buckley DL, Horsman A. Dynamic MR imaging of invasive breast cancer: correlation with tumour grade and other histological factors. Br J Radiol 1997;70:446-451.
12. Furman-Haran E, Schechtman E, Kelcz F, Kirshenbaum K, Degani H. Magnetic resonance Imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer 2005;104:708-718.
13. Szabo BK, Aspelin P, Kristoffersen WM, Tot T, Bone B. Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol 2003;13:2425-2435.
14. Stamper PC, Herman S, Klippenstein DL, et al. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology 1995;197:387-395.
15. Teifke A, Behr O, Schmidt M, et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 2006;239:351-360.
16. American College of Radiology. Breast imaging reporting and data system atlas (BI-RADS atlas). Reston, VA: American College of Radiology; 2003.
17. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 2007;120:1721-1730.
18. Ting Y-LT, Sherr D, Degani H. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res 1996;16:1381-1388.
19. Bartella L, Morris EA, Dershaw DD, et al. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006;239:686-692.
20. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
21. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 1987;508:333-348.
22. Hasse A, Frahm J, Hanicke W, Mattaei D. 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol 1985;30:341-344.
23. Bolan PJ, Meisamy S, Baker EH, et al. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003;50:1134-1143.
24. Balk HM, Su MY. Yu H, Mehta R, Nalcioglu O. Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA 2006;19:96-104.
25. Ercolani P, Valeri G, Amici F. Dynamic MRI of the breast. Eur J Radiol 1998;27:265-271.
26. Esserman L, Hylton N, George T, Weidner N. Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J 1999;5:13-21.
27. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989;170:681-686.
28. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging 2004;19:68-75.
29. Ali SH, O'Donnell AL, Balu D, et al. Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 2000;60:7094-7098.
30. Koukourakis MI, Manolas C, Minopoulos G, Giatromanolaki A, Sivridis E. Angiogenesis relates to estrogen receptor negativity, c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast. Int J Surg Pathol 2003;11:29-34.
31. Fuckar D, Dekanic A, Stifter S, et al. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol 2006;14:49-55.
32. Elkin M, Orgel A, Kleinman HK. An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. J Natl Cancer Inst 2004;96:875-878.
33. Klauber-DeMore N. Tumor biology of breast cancer in young women. Breast Dis 2005-2006;23:9-15.
34. Esserman LJ, Kumar AS, Herrera AF, et al. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol 2006;24:4603-4610.
35. van den Bosch MA, Daniel BL, Mariano MN, et al. Magnetic resonance imaging characteristics of fibrocystic change of the breast. Invest Radiol 2005;40:436-441.
36. Jinguji M, Kajiya Y, Kamimura K, et al. Rim enhancement of breast cancers on contrast-enhanced MR imaging: relationship with prognostic factors. Breast Cancer 2006;13:64-73.
37. Mitsuyama S, Anan K, Toyoshima S, et al. Histopathological predictors of axillary lymph node metastases in patients with breast cancer. Breast Cancer 1999;6:237-241.
38. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000;191:1-6.
39. González-Vela MC, Garijo MF, Fernández FA, Buelta L, Val-Bernal JF. Predictors of axillary lymph node metastases in patients with invasive breast carcinoma by a combination of classical and biological prognostic factors. Pathol Res Pract 1999;195:611-618.
40. Velanovich V, Szymanski W. Lymph node metastasis in breast cancer: common prognostic markers lack predictive value. Ann Surg Oncol 1998;5:613-619.
41. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;232:123-138.
42. Ramirez de Molina A, Gutierrez R, Ramos MA, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002;21:4317-4322.